Celgene

CELG

Delayed Nasdaq Other stock markets 02:30:00 21/11/2019 am IST			5-day change	1st Jan Change
108.2 ^USD	+0.10%		-1.97%	+68.89%

2023	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
2021	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

Update to Celgene Corporation's Equity Buyback Plan

January 24, 2013 at 11:12 pm IST

As of period ended on December 31, 2012, the company has repurchased 8,551,802 shares for $663.26 million.

Latest news about Celgene

Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	15/23/15	CI
Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	08/21/08	CI
Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	22/21/22	CI
Celgene Corporation Issues Notice of Redemption of Notes	23/21/23	CI
Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	04/21/04	CI
Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	05/21/05	CI
Amgen : Signs Licensing Agreement With Medicines Development for Global Health	23/20/23	MT
Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	05/20/05	MT
Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	23/20/23	CI
Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	22/20/22	CI
Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	26/20/26	CI
Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	11/20/11	CI
Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	04/20/04	CI
DISH Network : Democratic lawmaker presses antitrust enforcers on company ties, settlements	08/20/08	RE
Galecto, Inc. acquired PharmAkea, Inc. from Bay City Capital LLC and Celgene Corporation for $17.4 million	07/20/07	CI
GNS Healthcare, Inc. announced that it has received $28 million in funding from Cigna Ventures, Amgen Ventures, Celgene Corporation, Echo Health Ventures, Alexandria Venture Investments, LLC, Merck Global Health Innovation Fund, LLC, and another investor	07/20/07	CI
More drugmakers hike U.S. prices as new year begins	01/20/01	RE
Dealmakers eye cross-border M&A recovery as mega mergers roll on	31/19/31	RE
Oncorus, Inc. announced that it has received $89.6 million in funding from a group of investors	20/19/20	CI
Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug	21/19/21	RE
Celgene Corporation(NasdaqGM:CELG) dropped from S&P 500 Growth	21/19/21	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P TMI Index	21/19/21	CI
Celgene Corporation(NasdaqGM:CELG) dropped from INDUSTRIALS	21/19/21	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P 500 Value	21/19/21	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P Global 1200	21/19/21	CI

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Sector

More about the company

Celgene

Equities

CELG

Update to Celgene Corporation's Equity Buyback Plan

Latest news about Celgene

Chart Celgene

Company Profile